Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,173.9
9.1 (0.29%)

 

  • STI Straits Times Index
    3,173.9
    9.1 (0.29%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,598.3
    5.8 (0.36%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,331.0
    368.4 (1.48%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,572.4
    14.1 (0.40%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,068.6
    517.7 (1.81%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,633.3
    7.2 (0.11%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,492.6M
  • Value: 1,237.8M
  • Rise: 199
  • Fall: 127
  • Unch: 425

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Hatten Land0.079+0.009
Rex Intl0.310+0.005
Genting Sing0.795+0.015
Ntegrator Intl0.009-
Geo Energy Res0.410-0.010
RH PetroGas0.205-
Sembcorp Marine0.080-
MarcoPolo Marine0.028-0.001
BlackGoldNatural0.019-
ThaiBev0.715+0.005

World Indices

World Indices
Name Last Change
Nasdaq 14,897.3 +73.9
HSI 25,331.0 +368.4
HSCEI 8,966.2 +117.0
Jakarta 6,633.3 +7.2
Nikkei 225 29,068.6 +517.7
SSE Comp 3,572.4 +14.1
Shanghai A 3,743.9 +14.8
Shanghai B 278.0 +0.5
KOSPI 3,015.1 +26.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

PALLA PHARMA LTD PALLA PHARMA
Updated on 15 Oct 2021 (End of trading day)
Last (AUD): 0.300 Change: - High: 0.300 Remarks: -
Change (%): - Low: 0.300
Open 0.300 Yesterday's Close 0.3
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) - Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a -0.21466 Trailing EPS (AUD) e -0.36345 NAV (AUD) b 0.1239
PE a - Trailing PE f - Price / NAV b 2.4213
Dividend (AUD) d - Cash In Hand (AUD) g 0.0055 Issued & Paid-up Shares c 161,913,000
Dividend Yield (%) d - Price / Cash In Hand g 54.545 Treasury Shares h -
Beta - 75 Daysi 0.453 R-Squared - 75 Days(%)i 0.50 Market Cap (M) 48.574
Beta - 500 Daysi 0.426 R-Squared - 500 Days (%)i 0.80 Enterprise Value (M) 63.229
Piotroski F Score 1 Exchange Code PAL Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 75.91 Free Float (%) 71.0
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 29 Mar 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 19 Jun 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference PALLA PHARMA LTD ASX 48.574 - - 2.4213 -
Industry Pharmaceuticals: Major ASX 133.638 - - 7.1258 -
Local Peer STARPHARMA HOLDINGS LIMITED ASX 475.298 - - 7.6271 -
Local Peer RACE ONCOLOGY LTD ASX 473.340 - - 34.5085 -
Local Peer PYC THERAPEUTICS LIMITED ASX 461.235 - - 8.6826 -
Local Peer AFT PHARMACEUTICALS LTD ASX 393.631 55.506 55.510 11.6988 -
Local Peer RECCE PHARMACEUTICALS LTD ASX 165.089 - - 8.0508 -
Local Peer NOXOPHARM LTD ASX 156.347 - - 3.8351 -
Local Peer CRESO PHARMA LTD ASX 132.172 - - 4.9327 -
Local Peer EXOPHARM LTD ASX 84.894 - - 4.5000 -
Local Peer INVION LTD ASX 82.107 - - 17.5000 -
Local Peer PHARMAXIS ASX 54.519 - - 19.0476 -
Local Peer MEDLAB CLINICAL LIMITED ASX 53.037 - - 3.4989 -
Local Peer ONCOSIL MEDICAL LIMITED ASX 35.655 - - 3.0405 -
Other Local Peers ACRUX (ASX), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Global Peer JOHNSON & JOHNSON NYSE 424,619.024 28.858 23.899 6.1026 2.467
Global Peer PFIZER INC NYSE 232,621.568 24.191 17.586 3.3212 3.662
Global Peer ELI LILLY AND COMPANY NYSE 227,551.488 36.739 37.484 35.3100 1.244
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 202,860.219 24.982 22.555 3.7538 2.313
Global Peer MERCK & CO INC NYSE 198,282.212 28.057 35.592 5.9555 3.165
Global Peer ABBVIE INC NYSE 193,205.789 42.407 29.322 15.3715 4.422
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 186,577.819 58.379 49.477 11.9021 1.928
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 181,403.790 28.152 25.482 17.3508 1.314
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 129,682.340 - - 3.5232 3.184
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 123,441.019 8.794 17.825 1.6460 2.738
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), REPLIGEN CORP (NASDAQ), INNOVENT BIOLOGICS INC (HKEx), CANSINO BIOLOGICS INC (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ORGANON & CO (NYSE), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), SINOPHARM GROUP CO. LTD. (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), ALLAKOS INC (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), AKESO INC (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), INNOCARE PHARMA LTD (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), OPKO HEALTH INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), ERASCA INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), ADC THERAPEUTICS SA (NYSE), IGM BIOSCIENCES INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), EVEREST MEDICINES LTD (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP LIMITED (HKEx), OCUMENSION THERAPEUTICS (HKEx), CSTONE PHARMACEUTICALS (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), OLEMA PHARMACEUTICALS INC (NASDAQ), ZYMEWORKS INC (NYSE), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ABBISKO CAYMAN LTD (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), PROCAPS GROUP S A (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), Kimia Farma Tbk. (IDX), GOSSAMER BIO INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), IMMUNOTECH BIOPHARM LTD (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), KRONOS BIO INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), CK LIFE SCIENCES INTL HLDG (HKEx), KEROS THERAPEUTICS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), ANTENGENE CORP LTD (HKEx), IDEAYA BIOSCIENCES INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), GH RESEARCH PLC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), PETIQ INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), VERU INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), HUA MEDICINE (HKEx), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), WEREWOLF THERAPEUTICS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), AC IMMUNE SA (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), IGBB (Bursa), EVELO BIOSCIENCES INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), CLENE INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), ESSA PHARMA INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), FUSION PHARMACEUTICALS INC (NASDAQ), CYBIN INC (NYSE American), TCR2 THERAPEUTICS INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), XOMA CORP (NASDAQ), NEXIMMUNE INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BSTEAD (Bursa), CHECKPOINT THERAPEUTICS INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), DURECT CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), HARROW HEALTH INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), PHARMA (Bursa), ANGION BIOMEDICA CORP (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), TRICIDA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), OBSEVA SA (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), IMMUNIC INC (NASDAQ), ANNOVIS BIO INC (NYSE American), IMPEL NEUROPHARMA INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), INOZYME PHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), IP (SET), 180 LIFE SCIENCES CORP (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), SATSUMA PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), NOVAN INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), POLYPID LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), IX Biopharma (SGX), ENTERA BIO LTD (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), VTV THERAPEUTICS INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), GENPREX INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), KOTRA (Bursa), EDESA BIOTECH INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), IMARA INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), MEDIWOUND LTD (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), YUMANITY THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), Phapros Tbk. (IDX), OCUPHIRE PHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), PAK FAH YEOW INTERNATIONAL (HKEx), Hyphens Pharma (SGX), MANNATECH INC (NASDAQ), NOVA (Bursa), ABVC BIOPHARMA INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), BIOHLDG (Bursa), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), VIRPAX PHARMA INC (NASDAQ), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), RENOVORX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), ARIDIS PHARMACEUTICAL INC (NASDAQ), SEQLL INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), XORTX THERAPEUTICS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ACER THERAPEUTICS INC (NASDAQ), JCT (SET), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), SUNZEN (Bursa), NLS PHARMACEUTICS LTD (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), TITAN PHARMACEUTICAL INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.030
-9.09 %
10 Days --0.080
-21.05 %
20 Days -+0.030
+11.11 %
Medium Term Return 3 Months --0.090
-23.08 %
6 Months --0.170
-36.17 %
1 Year --0.385
-56.20 %
Long Term Return 2 Years --0.502
-62.59 %
Annualised Return Annualised --
-38.84 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.225 - 0.832 Change From 1 Year Low +0.075 % Change From 1 Year Low (%) +33.33
Change From 1 Year High -0.532 % Change From 1 Year High (%) -63.94
2 Years Range 0.225 - 1.075 Change From 2 Years Low +0.075 % Change From 2 Years Low (%) +33.33
Change From 2 Years High -0.774 % Change From 2 Years High (%) -72.08
5 Years Range 0.225 - 1.291 Change From 5 Years Low +0.075 % Change From 5 Years Low (%) +33.33
Change From 5 Years High -0.991 % Change From 5 Years High (%) -76.77
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Palla Pharma Ltd. manufactures and produces narcotic raw material for the international pharmaceutical industry. Its activities include narcotic raw materials, poppy seed production and distribution, active pharmaceutical ingredient and finished dosage production and distribution. The company was founded by Jarrod Ritchie in 2004 and is headquartered in Melbourne, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
15 Oct 2021 0.300 0.300 0.300 0.300 - -
14 Oct 2021 0.300 0.300 0.300 0.300 3,339 -
13 Oct 2021 0.325 0.330 0.300 0.300 71,109 -
12 Oct 2021 0.305 0.325 0.300 0.325 31,321 -
11 Oct 2021 0.330 0.330 0.310 0.310 37,691 -
08 Oct 2021 0.320 0.340 0.320 0.330 28,529 -
07 Oct 2021 0.305 0.310 0.305 0.310 65,026 -
06 Oct 2021 0.310 0.320 0.300 0.305 142,521 -
05 Oct 2021 0.390 0.390 0.325 0.325 22,689 -
04 Oct 2021 0.395 0.400 0.385 0.385 158,303 -
01 Oct 2021 0.375 0.405 0.335 0.380 412,997 -
30 Sep 2021 0.300 0.350 0.300 0.350 185,481 -
29 Sep 2021 0.290 0.300 0.290 0.300 78,847 -
28 Sep 2021 0.290 0.290 0.275 0.275 24,083 -
27 Sep 2021 0.265 0.285 0.260 0.285 111,797 -
24 Sep 2021 0.290 0.290 0.260 0.260 49,130 -
23 Sep 2021 0.270 0.282 0.265 0.270 108,473 -
22 Sep 2021 0.280 0.300 0.265 0.265 184,607 -
21 Sep 2021 0.265 0.280 0.250 0.280 92,427 -
20 Sep 2021 0.275 0.275 0.250 0.265 71,152 -
17 Sep 2021 0.260 0.275 0.255 0.270 98,586 -
16 Sep 2021 0.265 0.265 0.265 0.265 4,148 -
Summary
Current 2 Weeks
(04 Oct 2021 to 15 Oct 2021)
0.395 0.400 0.300 0.300 560,528 -
Previous 2 Weeks
(20 Sep 2021 to 01 Oct 2021)
0.275 0.400 0.250 0.380 1,318,994 -
4 Weeks from
(23 Aug 2021 to 17 Sep 2021)
0.350 0.400 0.300 0.270 4,724,061 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.